Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer
Status:
Completed
Trial end date:
2016-05-04
Target enrollment:
Participant gender:
Summary
The investigators planned a phase I study of preoperative CRT with capecitabine plus
temozolomide inpatients with locally advanced resectable rectal cancer: 1) the role of
temozolomide as a radiosensitizer has been well established, 2) hypermethylation (or low
expression) of MGMT promoter is associated with colorectal carcinogenesis, can be found in
20~40% of colorectal cancer patients, and this proportion could be adequate for validation as
its role of predictive biomarker, and 3) temozolomide can be additive or synergistic because
radiotherapy is now essential in the treatment of rectal cancer.